EGFR and non-small cell lung carcinoma: When risk score, age, sex, smoking history, EGFR mutation, TNM stage, brain metastasis, pathology, TKI, and surgery treatment were included into univariate and multivariate Cox regression analysis to balance the impact of clinical factors, risk score was an independent OS (HR = 2.27, 95% CI 1.65–3.13, P < 0.001) and PFS (HR = 1.86, 95% CI 1.37–2.52, P < 0.001) factor in NSCLC patients receiving EGFR-TKI treatment (Table 1).